Company / Current Liabilities
INOVIO PHARMACEUTICALS, INC. Current Liabilities History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Current Liabilities
$43.7M
FY2025
5-year range
$35.3M / $96.9M
FY2021-FY2025
Trend
+23.6%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Current Liabilities returned to growth in FY2025 after 2 years of decline, reaching $44M.
Based on SEC 10-K filings.
$44M in FY2025 with a 5-year CAGR of +0.9%.
Increased from $43M to $44M over the past 2 years.
Current Liabilities over time
Growth rates
- 3-Year CAGR
- -23.3%
- 5-Year CAGR
- +0.9%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of +0.9%, indicating consistent growth.
- In FY2025, current liabilities increased 23.6% year-over-year.
- Peak current liabilities was recorded in FY2022.
- Lowest current liabilities in the period was in FY2019.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 0.43 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Current LiabilitiesValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $43.7M | +23.6% |
| FY2024 | $35.3M | -17.0% |
| FY2023 | $42.6M | -56.1% |
| FY2022 | $96.9M | +47.3% |
| FY2021 | $65.7M | +57.6% |
| FY2020 | $41.7M | +30.4% |
| FY2019 | $32.0M | -9.4% |
| FY2018 | $35.3M | -0.3% |
| FY2017 | $35.4M | -19.2% |
| FY2016 | $43.8M | +39.3% |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026